Amarin Corporation plc (AMRN)
| Market Cap | 749.10M |
| Revenue (ttm) | 423.44M |
| Net Income (ttm) | -91.96M |
| Shares Out | 403.83M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | 500.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 349,221 |
| Open | 1.85 |
| Previous Close | 1.86 |
| Day's Range | 1.84 - 1.88 |
| 52-Week Range | 1.04 - 3.82 |
| Beta | 1.79 |
| Analysts | Hold |
| Price Target | 3.64 (+95.7%) |
| Earnings Date | Mar 7, 2023 |
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Moc... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for AMRN stock is "Hold." The 12-month stock price forecast is $3.64, which is an increase of 95.70% from the latest price.
News
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
Urges Shareholders to Vote “AGAINST” Sarissa's Proposals on the WHITE Proxy Card
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2...
Amarin to Present at SVB Securities Global Biopharma Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is sch...
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.
3 Penny Stocks to Sell in January Before They Peter Out
The changing of the calendar has brought a new sentiment to Wall Street. Many of 2022's biggest losers such as meme stocks, SPACs and penny stocks are suddenly enjoying strong rallies once again.
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
-- Board Refreshment Process Has Been Comprehensive, Independent and Transparent; Sarissa's Candidates Are Not Qualified Versus Recently Appointed Board Members -- -- Amarin Recognizes Shareholder Fru...
Sarissa Capital Calls Out Amarin's Sham Board Refreshment
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN):
Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations
Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.
Amarin Comments on Sarissa's Notice to Call a Special Meeting of Amarin Shareholders
Highlights Significant Board Refreshment, Operational and Financial Improvements and Engagement with Sarissa Capital Management Highlights Significant Board Refreshment, Operational and Financial Impr...
Sarissa Capital Submits Notice to Call a Special Meeting of Amarin Shareholders to Add Directors and Remove Chairman Per Wold-Olsen
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN):
Amarin's stock is up 17% on strong revenue estimates for 2022
U.S.-listed shares of Amarin Corp. PLC AMRN, +16.22% rallied about 17% in trading on Tuesday afternoon after the company shared better-than-expected sales estimates for 2022. In a news release and dur...
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements -- -- Amarin to Present at 41st Annual...
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
-- Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin's Board –-
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is sch...
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company's Presence and Expansion in Switzerland a...
Why Amarin (AMRN) Stock Might be a Great Pick
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for VASCEPA®/VAZK...
Amarin to Present at Jefferies London Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is sch...
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction B...
Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned ...
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
New Independent Directors Bring Significant International Experience in Healthcare and Finance
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior manage...
Amarin Board of Directors Issues Statement in Response to Sarissa
-- Highlights Active Board Refreshment Process -- -- Amarin Has Engaged Proactively and Frequently with Sarissa --
Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement regarding its ongoing discussions with Amarin Corporation plc (NASDAQ: AMRN) regarding b...